Innate Pharma SA

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 20, 2022, in Marseille. All resolutions were voted on in accordance with the Executive Board's recommendations. A total of 134 votes were cast out of a total of 32,598,725 shares giving right to 33,088,040 voting rights, representing a quorum of 40.88%.

Outcome of Innate Pharma's 2022 Annual General Meeting

Innate Pharma SA (NASDAQ:IPHA ) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Henry Wheeler - VP and Head of IR Mondher Mahjoubi - Chairman of Executive Board and CEO Joyson Karakunnel - Executive VP and Chief Medical Officer Yannis Morel - Executive VP of Product Portfolio Strategy and Business Development and Member of Executive Board Conference Call Participants Daina Graybosch - SVB Leerink Olga Smolentseva - Bryan Garnier Jingming Chen - Evercore Arthur He - H.C. Wainwright Operator Good morning, everyone.

Innate Pharma SA (IPHA) CEO Mondher Mahjoubi on Q1 2022 Results - Earnings Call Transcript

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma reports first quarter 2022 financial results and business update

Innate Pharma Reports First Quarter 2022 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (“SEC”) relating to an At-The-Market (“ATM”) program. Pursuant to this program, the Company may offer and sell to eligible investors (as described below) a total gross amount of up to $75 million of American Depositary Shares (“ADS”), each ADS representing one or

Innate Pharma Establishes an At-The-Market (“ATM”) Program on Nasdaq

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 10, 2022 at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2022. Speakers during the call will be: Mondher Mahjoubi, Chief Executive Officer Joyson Karakunnel, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice Pres

Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) has now dosed the first patient in its Phase 3 clinical trial, PACIFIC-9, evaluating durvalumab (PD-L1) in combination with monalizumab (NKG2A) or AstraZeneca's oleclumab (anti-CD73) in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who have not progressed following definitive platin

Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to hold its Annual General Meeting of shareholders on May 20, 2022

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma files its 2021 universal registration document and 2021 annual report on Form 20-F

Innate Pharma Files Its 2021 Universal Registration Document (Document d'enregistrement universel) and 2021 Annual Report on Form 20-F

Innate Pharma S.A. (IPHA) CEO Mondher Mahjoubi on Q4 2021 Results - Earnings Call Transcript

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma reports Full Year 2021 financial results and business update

Innate Pharma Reports Full Year 2021 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for full year 2021 financial results

Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma obtains €28.7M in non-dilutive financing in the form of State Guaranteed Loans

Innate Pharma Obtains €28.7m in Non-Dilutive Financing in the Form of State Guaranteed Loans

MARSEILLE, France--(BUSINESS WIRE)--First patient dosed in IPH6101/SAR443579 Phase 1/2 clinical trial in various blood cancers

Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers

Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an acceptable safety profile with a low discontinuation rate. Cohort 3 is exploring the triplet combination of monalizumab, cetuximab, and durvalumab in the first-line treatment of patients with recurrent or metastatic head and neck squamous cell cancer.

Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity

MARSEILLE, France--(BUSINESS WIRE)--Monalizumab combined with cetuximab and durvalumab demonstrates anti-tumor activity in first-line r/m head and neck cancer at ESMO IO 2021 congress

Innate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recurrent or Metastatic Head and Neck Cancer at ESMO Immuno-Oncology 2021 Congress

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to present monalizumab data at ESMO Immuno-Oncology 2021 Congress

Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in the Evercore ISI 4th Annual HealthConX Virtual Conference

Innate Pharma to Participate in the Evercore ISI 4th Annual HealthConX Virtual Conference

Innate Pharma S.A. (IPHA) CEO Mondher Mahjoubi on Q3 2021 Results - Earnings Call Transcript

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma Third Quarter 2021 Report

Innate Pharma Third Quarter 2021 Report

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma highlights new NK cell engager data with partner Sanofi at SITC

Innate Pharma Highlights New NK Cell Engager Data With Partner Sanofi at SITC Annual Meeting

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, November 16, 2021, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2021. Participating in the call will be Innate's Chief Executive Officer Mondher Mahjoubi, MD and Chief Medical Officer Joyson Karakunnel, MD, MSc, FACP. Details for the Virtual

Innate Pharma Announces Conference Call and Webcast for Q3 2021 Business Update

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2022 financial calendar: March 24, 2022: Publication of 2021 financial statements May 10, 2022: Publication of revenue for 1Q2022 May 20, 2022: Annual General Shareholders Meeting September 15, 2022: Publication of half year financial statements November 14, 2022: Publication of revenue for 3Q2022 All financial reports are released before marke

Innate Pharma 2022 Financial Calendar

A clinical trial with an experimental lung cancer drug produced some positive results.

Here's Why Innate Pharma Stock Is Rocketing Higher Today

Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology ( ESMO21 ) Congress 2021. The trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).

What Is Happening With Innate Pharma Stock On Friday?

The stock price of Innate Pharma SA (NASDAQ: IPHA) increased by over 30% pre-market. This is why it happened.

News for Innate Pharma SA Stock (IPHA)